Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Slow claps today again...get to 15 and ill give a “weeee” lol
Nice work on nndm...slow claps here. Hope you bought that dip. Gl
Gathering shares of NN/DM low 6 all week!
Looking a little better today, this is another long-term one but offers plenty of swings to trade
Hahah she got the hammer today
I'm watching it now though, lol
Looks like you were wrong...oops
PGEN: SEC Admin Proceeding, Cease and Desist Order:
https://www.sec.gov/litigation/admin/2020/34-89997.pdf
Good luck! Im still in it.
i think i`m going to bail.....might be topped out .....as long as "kirk the jerk"....is at the helm,( and i don`t mean James T Kirk )....take the money and run!................gla
* * $PGEN Video Chart 06-10-2020 * *
Link to Video - click here to watch the technical chart video
Financial Summary
BRIEF: For the three months ended 31 March 2020, Precigen Inc revenues increased 32% to
$29.8M. Net loss before extraordinary items decreased 42% to $29.9M. Revenues reflect Collaboration and licensing revenues increase of 80% to $10.7M, Service revenues increase of 23% to
$13.9M, Product revenues increase of 3% to $5M. Lower net loss reflects Research and development - Balancing val decrease of 28% to $18.3M (expense)...From Reuters May 29th...PGEN
* * $PGEN Video Chart 06-02-2020 * *
Link to Video - click here to watch the technical chart video
* * $PGEN Video Chart 02-14-2020 * *
Link to Video - click here to watch the technical chart video
news blasting everywhere, with some including reply from the subsidiary of XON defending itself, of claims that mosquito control program has had the opposite consequence, the creation of a super bug
* * $XON Video Chart 06-18-2019 * *
Link to Video - click here to watch the technical chart video
News: $XON Intrexon Corporation and Surterra Wellness Partner in $100mm Deal to Advance Commercial Scale Fermentation-based Cannabinoid Production
BUDAPEST, Hungary and ATLANTA , June 18, 2019 /PRNewswire/ -- Intrexon Corporation (Intrexon) (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve quality of life and health of the planet, and Surterra Wellness (Surterra), one of the fastest growin...
In case you are interested https://marketwirenews.com/news-releases/intrexon-corporation-and-surterra-wellness-partner-in-100mm-deal-to-advance-commercial-scale-fermentation-based-cannabinoid-production-8374956.html
News: $XON Intrexon's Subsidiary Precigen to Present at the JMP Securities Life Sciences Conference
GERMANTOWN, Md. , June 13, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and its wholly-owned Intrexon Health subsidiary Precigen, Inc. , a bi...
In case you are interested https://marketwirenews.com/news-releases/intrexon-s-subsidiary-precigen-to-present-at-the-jmp-securities-life-sciences-conference-8350192.html
* * $XON Video Chart 06-11-2019 * *
Link to Video - click here to watch the technical chart video
News: $XON Oxitec Successfully Completes First Field Deployment of 2nd Generation Friendly(TM) Aedes aegypti Technology
- First field trial achieved up to 96% suppression of target disease-transmitting mosquito populations in dense urban settings in Brazil - Results indicate an increase in cost effectiveness over the 1 st Generation with limited production requirements CAMPINAS, Br...
In case you are interested https://marketwirenews.com/news-releases/oxitec-successfully-completes-first-field-deployment-of-2nd-generation-friendly-tm-aedes-aegypti-technology-8289524.html
News: $XON Intrexon Announces Advances in Non-Browning GreenVenus(TM) Romaine Lettuce
DAVIS, Calif. , June 3, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced it is advancing GreenVenus ™ Romaine lettuce to commer...
In case you are interested https://marketwirenews.com/news-releases/intrexon-announces-advances-in-non-browning-greenvenus-tm-romaine-lettuce-8288400.html
$XON CEO Insider Buy of $1.8 MILLION!!!
Intrexon (NASDAQ:XON) Randal J Kirk (CEO)
Buy 273,367 shares @ $4.69 $1,282,091.23 5/24/2019
Intrexon (NASDAQ:XON) Randal J Kirk (CEO)
Buy 115,187 shares @ $4.70 $541,378.90 5/22/2019
* * $XON Video Chart 04-16-2019 * *
Link to Video - click here to watch the technical chart video
News: $XON Oxitec Signs New Multi-year Development Agreement to Apply 2nd Generation Technology to Control Soybean Looper
OXFORD, England , April 16, 2019 /PRNewswire/ -- Oxitec Ltd., a UK-based biotechnology company that pioneered the use of biologically-engineered insects to control disease-spreading mosquitoes and crop-destroying agricultural pests and a wholly-owned subsidiary of Intrexon (NASDAQ: X...
In case you are interested https://marketwirenews.com/news-releases/oxitec-signs-new-multi-year-development-agreement-to-apply-2nd-generation-technology-to-control-soybean-looper-8007928.html
let the shorts be with you! all the way up to 10
2 hours ago AQB aqua Bounty, just announced FDA cleared AQUabounty salmon. They can now sell it in the USA XON should do well Monday. AQB has skyrocketed
Apparently it is already clearer the course that this company will take in the next hours, days, weeks and months. A very wise growth onwards. Congratulations to all those who bought below $4.73. Just a big climb from now on!
* * $XON Video Chart 03-05-2019 * *
Link to Video - click here to watch the technical chart video
had a ton of this the last few years......had to dump last fall, and wrote off a pretty large loss..........KIRK`S -A-JERK!!
he does have his finger in just about every sector of science
law of averages.....sooner or later , the moron will hit one out of the park, with one of his subsids........today looks like dead cat.......but I`m getting ready to jump back into the cesspool....glta
LEVB also has deal with ISOLF. I own both ISOLF and XON
XON and LEVB announce CBD news, XON 68m float but LEVB only 6m float.
$XON trade signals predict a buy zone for the stock. Even though today had a downward trend, the stock is expected to change back in direction. The product development as well as the stock volume remain in good condition. #BluSignals
https://www.blusignalsystems.com/xon-stock-changes-direction-trade-signals-sense-trend/
have 24k shares...18k now long term......would be nice to see this break thru $20 this month......might take a little off the table.......been underwater on this for a while....watching it climb the stairs again!...WHAT A BEAUTIFUL SIGHT!.....glta
Making a leap here; Please correct me if i'm wrong...
If XON ( and partner)'s new synthesis and fermentation of the precursor to opiate production comes to market...And it is quicker and easier than current methods ( poppy bleeding); doesn't this have all kinds of juicy implications?
Does that mean the end of Poppy cultivation in the east and the funding of the Taliban?
Does that mean XON shares in the spoils ( profits) of the huge opiate industry ( and culpability)?
Does it become a major security liability?
And so on.
OOps...Sorry, correction
" Intrexon's Industrial Products Division has demonstrated microbial production of cannabinoids that has potential to provide >20-fold reduction in Cost Of Goods with reduced environmental impacts for THC and CBD versus current synthetic and extraction-based routes; "
Oh boy:
XON announced a cost efficient synthesis of CBD and THC that'll be 30% cheaper than "current methods".
That ought'a stir things up!
added 5k under $12 beginning of feb....helped knock down average....been underwater on this one for 6 months....nice to be green again....back to $30..glta
BREAKING: Traders circulating an unconfirmed chatter of Intexon Corp $XON interest to acquire Oragenics $OGEN
ActoBio clinical trial for treatment of Type 1 Diabetes
News Release Issued: Mar 29, 2018 (9:26am EDT)
To view this release online and get more information about Intrexon Corporation visit: http://investors.dna.com/2018-03-29-ActoBio-Therapeutics-Greenlighted-by-FDA-to-Commence-a-Phase-Ib
-IIa-Trial-with-AG019-for-the-Treatment-of-Early-Onset-Type-1-Diabetes
ActoBio Therapeutics Greenlighted by FDA to Commence a Phase Ib/IIa Trial with AG019 for the Treatment of Early Onset Type 1 Diabetes
A unique combination approach to oral tolerance made possible by L. lactis therapeutic protein delivery
Photos(1)
GHENT, Belgium, March 29, 2018 /PRNewswire/ -- ActoBio Therapeutics, a wholly owned subsidiary of Intrexon Corporation (NYSE: XON) and innovative biotechnology company focused on a new class of orally delivered biopharmaceuticals, and Intrexon T1D Partners LLC, have been granted allowance by the U.S. Food and Drug Administration (FDA) for their Investigational New Drug (IND) application to initiate a Phase Ib/IIa study for the treatment of early onset type 1 diabetes (T1D) with AG019, an innovative disease-modifying approach to induce immune tolerance in T1D. Currently no disease-modifying treatment for T1D is available, and standard of care is primarily based on exogenous insulin and diet regulation in combination with lifestyle modification.
AG019 is an oral capsule formulation composed of engineered L. lactis delivering the autoantigen human proinsulin and tolerance-enhancing cytokine IL-10. AG019 is designed to reduce T1D pathology by re-establishing immunological tolerance to islet antigens via the production of regulatory T-cells. Preclinical tests in new-onset diabetes animal models demonstrated stable reversion to normoglycemia after treatment with AG019 (L. lactis expressing IL-10 and human proinsulin) in approximately 60% of mice. The most effective treatment effects were seen for AG019 in combination with short-term treatment with an anti-CD3 monoclonal antibody with a maximum level of diabetic reversion of 89% when treatment started at early diabetes. AG019 also preserved residual ß-cell function, halted insulitis progression and increased the frequency of regulatory T cells.
ActoBio Therapeutics Logo
"With ActoBio's AG019, I see for the first time the prospect of a disease-modifying treatment for type 1 diabetes patients, mostly children and young adults. The preclinical tests of AG019 showed a significant diabetes remission rate when treatment started at early stage. It could be a real game changer in disease management, which currently exists in life-long insulin dependence and adapted lifestyle. Together with my patients, my team is looking forward to participate in clinical studies to further develop this application," commented Prof. Chantal Mathieu, head of the Diabetes division of R&D at the Leuven University and head of Clinical and Experimental Endocrinology University Hospital Leuven Belgium.
"Pre-clinical tests with AG019 combined with an anti-CD3 mAb showed to be the most efficacious treatment. We and our partner are proud to achieve this important milestone in the development of what could be the first true disease-modifying treatment of type 1 diabetes. We soon will start the clinical trials in association with specialized institutes in Europe and North America," commented Pieter Rottiers, PhD, CEO of ActoBio Therapeutics.
About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is Powering the Bioindustrial Revolution with Better DNA™ to create biologically-based products that improve the quality of life and the health of the planet. Intrexon's integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon, on Facebook, and LinkedIn.
About ActoBio Therapeutics, Inc.
ActoBio Therapeutics, Inc. is pioneering a new class of microbe-based ActoBiotics® biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The ActoBiotics® platform produces biologics through oral or topical administration with treatment applications across many diseases including oral, gastrointestinal, and autoimmune/allergic disorders. This cost-effective approach is being developed to provide safer and more efficacious treatments than injectable biologicals. ActoBio Therapeutics has a strong R&D pipeline with the latest stage candidate in Phase 2b and an extensive portfolio of candidates ready for clinical development across a number of potential indications.
About Intrexon T1D Partners
Intrexon T1D Partners is a private company organized to develop and commercialize products through the ActoBiotics® platform to treat type 1 diabetes. The company is a 50/50 joint venture between ActoBio Therapeutics and a select group of external investors.
Trademarks
Intrexon, ActoBio Therapeutics, ActoBiotics, Powering the Bioindustrial Revolution with Better DNA, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.
Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.
For more information, contact:
Investor Contact:
Thomas Shrader, PhD
Vice President, Communications & Strategy
tshrader@intrexon.com
Corporate Contact:
Marie Rossi, PhD
Director, Technical Communications
Tel: +1 (301) 556-9850
publicrelations@intrexon.com
Nice day for XON. Now for the real question, will they give all this back next week or is this finally the start of a long awaited uptrend.
xon beats by $0.07
excellent conference call...
Statement of Changes in Beneficial Ownership (4)
KIRK Jan 31 bot 70,000 shares
FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
1. Name and Address of Reporting Person *
KIRK RANDAL J 2. Issuer Name and Ticker or Trading Symbol
INTREXON CORP [ XON ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__ X __ Director __ X __ 10% Owner
__ X __ Officer (give title below) _____ Other (specify below)
Chief Executive Officer
(Last) (First) (Middle)
C/O THIRD SECURITY, LLC, 1881 GROVE AVENUE 3. Date of Earliest Transaction (MM/DD/YYYY)
1/31/2018
(Street)
RADFORD, VA 24141
(City) (State) (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
6. Individual or Joint/Group Filing (Check Applicable Line)
_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 1/31/2018 A 54384 (1) A $14.71 (1) 940875 I by Third Security (3)
Common Stock 1/31/2018 A 15384 (2) A $13.00 (2) 14749589 I by R.J. Kirk DOT (3)
Common Stock 7782622 I by Kapital Joe (3)
Common Stock 8325000 I by TSCP V (3)
Common Stock 311287 I by Staff 2001 (3)
Common Stock 1403 I by Lotus (3)
Common Stock 139052 I by JPK 2008 (3)
Common Stock 140007
nice to see this heading north again.....if it can break $15, and hold for a few days I think we`re good...last 6 months have sucked!...glta
Followers
|
49
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
412
|
Created
|
08/24/13
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |